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Oncoproteomics aims to the discovery of molecular markers, drug targets, and pathways
by studying cancer specific protein expression, localization, modification, and interaction.
Cell surface proteins play a central role in several pathological conditions, including cancer
and its metastatic spread. However, cell surface proteins are underrepresented in pro-
teomics analyses performed from the whole cell extracts due to their hydrophobicity and
low abundance. Different methods have been developed to enrich and isolate the cell
surface proteins to reduce sample complexity. Despite the method selected, the primary
difficulty encountered is the solubilization of the hydrophobic transmembrane proteins
from the lipid bilayer.This review focuses on proteomic analyses of metastasis-associated
proteins identified using the cell surface biotinylation method. Interestingly, also certain
intracellular proteins were identified from the cell surface samples. The function of these
proteins at the cell surface might well differ from their function inside the cell.
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ROLE OF CELL SURFACE PROTEINS IN CANCER
PROGRESSION AND METASTASIS
Cell surface forms a physical barrier between the cell and its
environment simultaneously mediating multiple crucial signaling
events. It is mainly composed of proteins that are embedded in the
lipid bilayer of plasma membrane. These proteins can be classified
as transmembrane proteins with one or multiple transmembrane
domains, lipid anchored proteins, or peripheral membrane pro-
teins that are attached to other cell surface proteins or peripheral
regions of the lipid bilayer.
Cell surface molecules play an important role in mediating cell–
cell interactions and signaling between the cells and between the
cells and their environment. In general, cell surface proteins can be
divided into ligand-gated ion channels, G-protein linked, enzyme-
linked, and cell adhesion receptors (Kabbani, 2008). Especially
G-protein and enzyme-linked receptors are important in sensing
extracellular ligands, such as growth factors and hormones, which
then participate in the complex intracellular signaling pathways.
In addition, cell adhesion proteins are vital for the cell attachment
to the extracellular matrix (ECM) components, such as collagens,
laminins, and proteoglycans. Cell adhesion is also crucial for cell
migration and communication between the neighboring cells.
Composition of the cell surface is dynamic and changes con-
stantly due to the internalization, secretion, and shedding of
proteins in response to internal and external stimuli. Cell surface
undergoes modifications during different developmental stages
and its structure varies between different cell types. Importantly,
cell surface molecules play a central role in several pathological
conditions, including cancer and its metastatic spread (Kawaguchi,
2005; Dowling et al., 2008).
A key event in cancer progression is the acquisition of an inva-
sive phenotype that allows cancer to spread to distant organs in
the body and form metastatic lesions. Metastatic dissemination,
rather than the primary tumor, causes 90% of cancer deaths. Can-
cer metastasis can be divided into the following steps; detachment
from the primary tumor, invasion of the lymphatics and/or blood
vessels, transport to distant organs, extravasation, and prolifer-
ation at the secondary site (Fidler, 2003). This cascade is com-
plicated by the fact that different tumor types metastasize to a
different set of organs (Auerbach et al., 1987; Johnson et al., 1991;
Nguyen et al., 2009). The importance of the cell surface in the
metastasis has been recognized already during 1970s and 1980s
(Davey et al., 1976; Pearlstein et al., 1980; Poste and Nicolson, 1980;
Fogel et al., 1983). Cell surface proteins play an important role in
the signaling and adhesive interactions between the tumor and
stromal cells during the metastatic dissemination and during the
organ specific homing of metastatic cells (Ruoslahti and Rajotte,
2000; Brown and Ruoslahti, 2004; Dowling et al., 2008; Brooks
et al., 2010). Cell surface proteins are also optimal targets for can-
cer therapies due to their accessibility. Currently, while making
only about 22% of all proteins encoded in the human genome, cell
surface molecules represent two-thirds of the protein-based drug
targets (Hopkins and Groom, 2002; Overington et al., 2006).
CELL SURFACE ONCOPROTEOMICS
Oncoproteomics aims to the discovery of molecular markers, drug
targets, and pathways by studying cancer specific protein expres-
sion, localization, modification, and interaction. As stated above,
the cell surface plays a crucial role in cancer metastasis. Therefore,
it is important to discover the differences between the surface of a
normal or a non-metastatic cancer cell and a metastatic one. How-
ever, the poor solubility and low abundance of cell surface proteins
lead to their under representation in proteomic studies performed
from the whole cell extracts. With the aid of protein fractionation
and more sensitive technologies, such as mass spectrometry based
proteomics, researches have revealed novel proteins, and suggested
new functions for known proteins. Different methods have been
developed to isolate and enrich the cell surface and/or plasma
membrane proteins for proteomic analyses (recently reviewed in
Elschenbroich et al., 2010). However, it is important to notice
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that the cell surface and plasma membrane fractions are not com-
pletely identical. Ligands bound to their receptors, for example,
can be considered as cell surface proteins but not as true plasma
membrane proteins due to their lack of direct contact with it.
In addition, during the preparation of a plasma membrane frac-
tion, intracellular proteins attached to the plasma membrane are
also isolated. These, however, cannot be considered cell surface
proteins.
The most commonly used method for the isolation of plasma
membrane fraction is homogenization combined with membrane
density separation (Elschenbroich et al., 2010; Leth-Larsen et al.,
2010). Plasma membrane proteins can also be isolated by the elec-
trostatic attachment of cationic colloidal silica to the membranes
(Rahbar and Fenselau, 2004) combined with Triton X-114 phase
partitioning (Mathias et al., 2011). As most secreted and cell sur-
face proteins are glycosylated, they can be isolated with the aid of
the cell surface capture technique (CSC) after labeling of the glycan
moieties (Wollscheid et al., 2009), with a lectin affinity approach
(Wang et al., 2008), and with metabolic labeling of the glycans
followed by affinity isolation (Yang et al., 2011). Due to their acces-
sibility, cell surface proteins can easily be labeled with a membrane-
impermeable biotin and isolated with streptavidin-linked beads
from the cell extracts (Elia, 2008). We have recently optimized
the isolation of biotinylated cell surface proteins (Karhemo et al.,
2012). The flow chart of the optimized method is shown in
Figure 1. Using the labeling methods, all proteins accessible for
the labeling reagent e.g., ligands bound to their receptors are iso-
lated and analyzed with downstream applications. When adherent
cell cultures are used as a starting material secreted and ECM pro-
teins can also be isolated. Despite the isolation method of the cell
surface proteins, the primary difficulty encountered is the solu-
bilization of the hydrophobic transmembrane proteins from the
lipid bilayer. This is performed by the aid of different detergents,
which should be chosen carefully to ensure that they do not inter-
fere with the downstream applications. The use of detergents in
membrane protein analyses has been recently reviewed (Seddon
et al., 2004). Importantly, in the affinity enrichment of cell surface
proteins with biotinylation or other labeling methods, only the
proteins soluble in the detergent used will be isolated. To obtain
the most comprehensive picture of cell surface proteins multiple
isolations with different detergents are needed.
Following isolation cell surface proteins are analyzed, identi-
fied, and quantified with proteomics methods. Two dimensional
(2D) gel electrophoresis is a conventional proteomics tool where
proteins are first separated according to their isoelectric point (iso-
electric focusing, IEF). The second dimension is an SDS-PAGE
gel, which is stained to visualize the protein spots. The 2D-gel
electrophoresis has very high resolution and it can separate post-
translational variants of a single protein. With this high resolution
one can assume that one protein spot represents a single pro-
tein and changes in the spot volume can be used to quantitate the
expression differences between the analyzed samples. The proteins
within interesting spots can be in-gel digested and identified using
mass spectrometry. Hydrophobic membrane proteins, however,
often precipitate at their isoelectric point in the first dimension.
Therefore they do not enter the second dimension gel and are lost
from the analyses. The use of 2D-electrophoresis to analyze mem-
brane proteins has been recently reviewed (Rabilloud et al., 2008).
Shotgun proteomics is a method used to identify proteins from
complex mixtures with high performance liquid chromatography
FIGURE 1 | Schematic representation of the optimized isolation of biotinylated cell surface proteins.
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combined with mass spectrometry. This is the most common
method, with or without separation of the samples in an SDS-
PAGE gel, used for identification of proteins from cell surface
fractions. To create a quantitative method, various label-based and
label-free approaches have been developed for the quantitation of
differentially expressed proteins from gel free analyses (Coombs,
2011).
METASTASIS-ASSOCIATED CELL SURFACE PROTEINS
IDENTIFIED USING PROTEOMICS
To identify proteins essential for cancer metastasis, researchers
have often compared protein expression between closely related
or isogenic metastatic and non-metastatic cells. The use of iso-
genic cell pairs diminishes the genetic variation. Thus, the dif-
ferential expression of a protein is more likely to be associated
with the metastatic behavior than when using non-isogenic cell
lines. Table 1 shows a selection of metastasis-associated proteins
identified from different models with comparative cell surface
oncoproteomics using either the cell surface biotinylation (Conn
et al., 2008; Roesli et al., 2009; Luque-Garcia et al., 2010; Karhemo
et al., 2012) or the plasma membrane isolation method (Leth-
Larsen et al., 2009). We selected proteins to the Table 1 only
if the differential expression and the cell surface localization of
non-conventional cell surface proteins were validated in these
studies.
In addition to the identifications of known players in metastasis
novel candidate metastasis-associated proteins were identified in
these studies. Some of these candidates are conventionally consid-
ered to reside inside the cell and might represent contamination of
the cell surface fraction with the intracellular proteins. However,
the cell surface expression of some of the intracellular proteins
was confirmed by other methods in these studies. The cell surface
localization of conventional intracellular proteins has also been
reported in other studies (rewieved in Butler and Overall, 2009).
For an unknown reason tumor cells appear to display extracel-
lularly proteins that normally reside inside the cell. The function
of an intracellular protein at the cell surface might well differ
from its function inside the cell. The cell surface function of these
non-classical cell surface proteins might also be affected by post-
translational modifications that change their physical properties,
solubility, localization, and interactions with other proteins.
Below we will review some known and novel metastasis-
associated proteins identified using the comparative cell surface
proteomics. Interestingly, only minor overlap exists between pro-
teins identified in different experimental models or even when
the same model has been analyzed using different methods for
the sample preparation, antigen detection, and protein quantifi-
cation. Only three common proteins were identified (HLA-DRB1,
HLA-DRA1, and ITGA6) in two studies analyzing the cell surface
proteins of a non-metastatic and metastatic pair of human breast
cancer/melanoma cell line MDA-MB-435 either using the plasma
membrane isolation (Leth-Larsen et al., 2009) or the cell surface
biotinylation method (Karhemo et al., 2012). Comparison of dif-
ferent studies is complicated by the fact that one protein might
have multiple names or different accession numbers in different
databases. In the future, it would be interesting to analyze the mol-
ecular pathways and interactomes of all identified and validated
metastasis-associated cell surface proteins in a bioinformatics plat-
form. In this review, the comparison was performed manually for
a short overview. Interestingly, upregulation of different forms
of protein tyrosine phosphatases (PTPs) have been identified on
the surface of the metastatic cells in three of the studies analyzed
(Conn et al., 2008; Roesli et al., 2009; Karhemo et al., 2012). PTPs
can either promote or suppress tumor progression and metastasis
via either enhancing or suppressing cell surface receptor tyrosine
kinase signaling (reviewed in Sastry and Elferink, 2011).
The junction plakoglobin (JUP, catenin gamma), reported to
be overexpressed in the metastatic colorectal cancer cells (Luque-
Garcia et al., 2010), was found to be downregulated in the highly
invasive and metastatic fibrosarcoma cells (Conn et al., 2008).
The differential expression was not, however, validated in the
fibrosarcoma model and the Western blot validation performed
in the colorectal cancer showed only 1.4-fold higher expression
in the metastatic cell line. According to immunohistochemi-
cal analysis of colorectal cancer specific tissue microarrays the
expression of JUP was higher in the epithelial cells of tumor
tissue than in their normal counter parts. In addition, most of
the late stage tumors showed a clear overexpression of the pro-
tein (Luque-Garcia et al., 2010). The contradictory results in
these studies could be explained by the different origin of the
tumor cell lines and by the different localization of the metasta-
tic site (liver vs. lungs). According to a recent review on the
function of JUP in cancer and metastasis it appears generally
act as a tumor/metastasis suppressor protein (Aktary and Pasdar,
2012).
The ecto-5′-nucleotidase (5′-nucleotidase, ecto-5′-NT, CD73),
overexpressed in the metastatic variant of the MDA-MB-435 cells
(Leth-Larsen et al., 2009) has been shown to affect tumor growth
by limiting the antitumor T-cell immunity via adenosine receptor
signaling. Adenosine is an important metabolite released by cancer
cells to establish physiological conditions conducive for tumori-
genesis (Spychala, 2000). Moreover, it has been reported that a
small interfering RNA (siRNA) against the ecto-5′-NT effectively
inhibits invasion and migration of the highly aggressive human
MDA-MB-231 breast cancer cells and prevents their adhesion to
the ECM (Zhi et al., 2007). The role of ecto-5′-NT as a promis-
ing target for tumor therapy has been recently discussed (Zhang,
2010).
Roesli et al. (2009) reported overexpression of the adenylate
kinase 2 (Ak2, Adk2) on the surface of the metastatic F9DR
murine terato-carcinoma cells compared to the non-metastatic
F9B9 cell line. Based on the microarray data Ak2 is also upreg-
ulated in the metastatic pancreatic endocrine neoplasms (Hansel
et al., 2004). Ak2 is thought to be a mitochondrial protein that
catalyzes a reversible transfer of the terminal phosphate group
between ATP and AMP (Dzeja et al., 1998) and plays a key role
in hematopoiesis. In addition, Ak2 is involved in energy metabo-
lism and nucleotide synthesis (Lagresle-Peyrou et al., 2009). Roesli
et al. (2009), however, confirmed that Ak2 localized on the cell sur-
face of the metastatic cells by analyzing the optical sections of the
confocal microscopic images. Interestingly, Ak2 has been shown
to play a role in bovine sperm flagella movement (Schoff et al.,
1989). Further studies are needed to reveal the function of Ak2 at
the cell surface of the metastatic cells.
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The junctional adhesion molecule C (JAM-C) was reported to
be overexpressed on the surface of the invasive HT-1080 fibrosar-
coma cells as compared to its non-invasive counterpart (Conn
et al., 2008). Overexpression of JAM-C in the invasive HT-1080
cells also significantly decreased the life span of tumor-bearing
mice (Fuse et al., 2007). JAM-C, together with JAM-A and B,
belongs to the immunoglobulin subfamily and is expressed by
leukocytes and platelets as well as by epithelial and endothelial
cells. It localizes to cell-cell contacts and is specifically enriched at
tight junctions making it an interesting candidate for functional
studies in metastasis. A more detailed description of junctional
adhesion molecules can be found in Ebnet et al. (2004) and
Bradfield et al. (2007).
We recently identified CD109, PTGFRN, and ART3 as novel
metastasis-associated candidate proteins (Karhemo et al., 2012).
CD109 is a GPI-linked cell surface protein expressed on the sur-
face of activated platelets (Smith et al., 1995). It negatively regulates
TGFB1 signaling in keratinocytes (Finnson et al., 2006; Hagiwara
et al., 2010). Shedding of CD109 by mesotrypsin has been shown
to be important for the malignant growth of breast cancer cells
in a three dimensional organotypic cell culture (Hockla et al.,
2010). In addition, expression of its transcript has been linked
to melanoma in a transgenic melanoma mouse model (Ohshima
et al., 2010). However, the function of CD109 in invasion and
metastasis is unknown. Expression of PTGFRN positively corre-
lates with the metastatic status of human lung tumors (Guilmain
et al., 2011). PTGFRN associates with and inhibits the bind-
ing of prostaglandin F2α to its receptor (Orlicky, 1996). It also
participates in the tetraspanin web (Charrin et al., 2001, 2003;
Stipp et al., 2001; Guilmain et al., 2011). The tetraspanin web
proteins either promote or suppress tumor invasion and metas-
tasis depending on the composition of the tetraspanin-enriched
microdomain on the cell surface (Richardson et al., 2011). The
function of PTGFRN in the tetraspanin web is unknown. Based
on its overexpression on the metastatic cell line, it might par-
ticipate in functions promoting metastasis. Not much is known
about the function of ART3 (Ecto-ADP-ribosyltransferase 3),
which hampers its functional analysis in metastasis. Due to the
lack of proper antibodies against ART3, we were only able to val-
idate its overexpression in the metastatic cell line at the mRNA
level (Karhemo et al., 2012). Ecto-ADP-ribosyltransferases are
a group of cell surface enzymes that reversible transfer ADP-
ribose groups onto target proteins thus modifying their func-
tion. The ADP-ribosylation of cell surface proteins provides
sophisticated regulatory mechanisms for cell communication
making ART3 as an interesting target in functional studies of
metastasis.
IN VIVO VALIDATION OF THE RESULTS
As stated in the previous sections, composition of the cell
surface changes constantly in response to environmental stim-
uli. When tumor cells are cultured in vitro they lack the 3-
dimensional microenvironment and contacts with stromal cells
that the metastatic tumor cell encounters while growing both at
the primary and secondary sites. For these reasons, it is impor-
tant to further validate the obtained in vitro results using in vivo
models. As seen in Table 1 the differential expression of some of
the identified proteins was validated in vivo either in xenograft
tumors derived from the same cells that were used in the pro-
teomics study or in patient material. In addition to the in vivo
validation, it is as important to perform functional assays to
reveal mechanisms underlying the differential expression and the
role of the identified proteins in the metastatic process. From
the studies reviewed here, only the function of tissue factor was
validated in invasion and metastasis (Conn et al., 2008). In the
future it might be important to focus on the identified metastasis-
associated cell surface proteins to reveal their interacting partners
and pathways they are involved in. Moreover, significance of the
cell surface localization of the intracellular proteins needs to be
further studied.
In order to discover metastasis-associated endothelial markers
in vivo biotinylation of the vasculature of liver metastasis was per-
formed (Borgia et al., 2010). Methods that would allow analysis
of cell surface proteomes of primary tumors and their matched
metastases from paraffin embedded tissue samples would also
greatly facilitate the identification of in vivo contributors and pos-
sible drug targets. In addition, it would be beneficial to analyze
the expression changes of stromal cell surface proteins at the sec-
ondary sites in response to metastatic tumor cells (Garin-Chesa
et al., 1990; Huang et al., 2005).
CONCLUDING REMARKS
Reduction of sample complexity by cell fractionation and subcel-
lular proteome analysis allows an in-depth analysis of intermediate
and low abundant proteins. Cell surface biotinylation is an excel-
lent method to identify known and novel metastasis-associated
cell surface proteins from various models. In addition, it can be
used to discover novel localizations for already known proteins.
When using the cell surface biotinylation method, selection of
detergents is of utmost importance and influences the type of
proteins that will be identified with the downstream applications.
The interesting novel metastasis-associated protein candidates
identified need further functional validation to resolve their role
in metastatic spread of tumors and possible use as novel drug
targets.
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